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Abstract
Waldenstrom’s Macroglobulinemia is a low-grade B-cell lymphoma characterized by the presence of lymphoplas-
macytic cells in the bone marrow and a monoclonal immunoglobulin M in the circulation. Recent evidences sup-
port the hypothesis that epigenetic modifications lead to Waldesntrom cell proliferation and therefore play a
crucial role in the pathogenesis of this disease. Indeed, while cytogenetic and gene expression analysis have
demonstrated minimal changes; microRNA aberrations and modification in the histone acetylation status of pri-
mary Waldenstrom Macroglobulinemia tumor cells have been described. These findings provide a better under-
standing of the underlying molecular changes that lead to the initiation and progression of this disease.
Introduction
First introduced by C.H. Waddington in 1939 to name
“the causal interactions between genes and their pro-
ducts, which bring the phenotype into being”,t h et e r m
“epigenetics” was later defined as heritable changes in
gene expression that are not due to any alteration in the
DNA sequence [1]. The best-known epigenetic markers
are DNA methylation and histone acetylation. Moreover,
all these phenomena are finely regulated in different
manners, such as through microRNAs (miRNAs) [2].
Waldenström’s Macroglobulinemia (WM) is a low-
grade B-cell lymphoma characterized by the presence of
lymphoplasmacytic cells in the bone marrow (BM) and a
monoclonal immunoglobulin M in the circulation [3,4].
The most common risk factor for WM is IgM MGUS
(monoclonal gammopathy of undermined significance),
which is associated with the presence of a small IgM pro-
tein in the circulation and minimal involvement (< 10%
lymphoplasmacytic cells) in the bone marrow, with the
absence of symptoms or signs of the disease. The risk of
progression of IgM MGUS is the highest in all types of
MGUS with about 5-10% risk of progression per year.
While WM cells showed minimal changes at cytoge-
netic studies and gene expression analysis [5], primary
WM tumor cells present with a miRNA signature that
differentiates them from their normal counterpart.
Among deregulated miRNAs, miRNA-155 has been
shown to play a pivotal role in the biology of this dis-
ease both in vitro and in vivo. Moreover, other miRNA
c h a n g e si nW Mc e l l s ,s u c ha st h ed o w n - r e g u l a t i o no f
miRNA-9*, has been proven to modulate the histone
acetylation status in WM cells [6]. These findings sup-
port the idea that epigenetic modifications are crucial in
the pathogenesis of WM. Importantly, these observation
provide the preclinical rational for testing miRNA-based
therapeutical approaches for the treatment of WM dis-
ease (Figure 1).
In this review, we will focus on the role of miRNAs and
histone acetylation as key regulators of WM biology.
miRNA signature characterizes primary WM tumor cells
miRNAs constitute a class of small, non-coding, 18-24
nucleotide RNAs, described for the first time in the
nematode Caenorhabditis elegans [7]. By repressing sev-
eral target mRNAs, mature miRNAs play a pivotal role
in regulating development, cell differentiation, apoptosis,
and cell proliferation [8-10]. Importantly, miRNAs have
been described to play roles in both solid tumors and
hematologic malignancies [11-13]. We have recently
performed miRNA studies in WM, and through unsu-
pervised clustering, we showed that WM clonal cells
present with a miRNA signature that differs from that
of their normal counterpart. Importantly, seven miRNAs
were specifically different between WM patients and
healthy individuals: among them, miRNA-363*, -206,
-494, -155, -184, -542-3p demonstrated increased
expression in WM patients; whereas miRNA-9*
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Predicted targets of the increased miRNAs in WM
patients included tumor suppressors, cell cycle inhibi-
tors, cytokine signaling suppressors and tyrosine phos-
phatases. Conversely, predicted target genes for the
decreased miRNAs in WM included protein kinases,
oncogenes and transcription factors. In addition, we
showed that several protein kinases, transcription fac-
tors, and cell cycle regulators were up-regulated in WM
patients including protein kinase C, serine/threonine
kinase 24, mitogen-activated protein kinase kinase
kinase 7, E2F- and pre-B-cell leukemia-transcription fac-
tors, as well as cyclin D2 and cyclin-dependent kinase
inhibitor [14], suggesting that miRNAs may play a cru-
cial role in WM pathogenesis.
miRNA-155 is expressed from an exon of the non-
coding BIC gene [15]. Its role as oncogenic miRNA and
its involvement in the initiation and progression of can-
cers has been reported in several hematologic malignan-
cies, including diffuse large B-cell lymphomas, chronic
lymphocytic leukemia and primary mediastinal B-cell
lymphomas, where it has shown to be highly expressed
[16-18]. Based on the evidence that miRNA-155 is
increased in primary WM cells, we subsequently con-
ducted in vitro and in vivo studies to better define the
functional and biological role of miRNA-155 in support-
ing WM cell pathogenesis; and it has been demonstrated
that DNA synthesis was significantly reduced in
miRNA-155 knocked-down cells compared to control
cells [14]. Similarly, miRNA-155 modulated cell cycle
progression in WM cells, as demonstrated by an
increased % of cells in G1-phase, together with a
decreased % of cells in S-phase. These findings were
v a l i d a t e da tg e n ee x p r e s s i o np r o f i l i n gt h a ts h o w e d
increased expression of cyclin-dependent kinase inhibi-
tors (p18, p19, p21, p27); decreased expression of
cyclin-dependent kinases-2, -4, -6, as well as cyclins D1,
D2, D3 and E; and increased expression of p53 with
decreased expression of its negative regulator (Mdm2)
in the miRNA-155 knockdown WM cells compared to
controls. In addition, the impact of miRNA-155 knock-
down on signaling cascades regulating proliferation was
next investigated showing that miRNA-155 knockdown
strongly inhibited ERK- and AKT-phosphorylation, as
well as p-GSK3a/b and p-S6R, both AKT downstream
target proteins.
It has been clearly demonstrated that BM microenvir-
onment confers growth advantages to and induces drug
resistance in malignant cells [19]. Therefore, the role of
miRNA-155 in regulating WM cell proliferation in the
context of BM milieu has been investigated, showing a
significant inhibition of adhesion to fibronectin in
miRNA-155 knockdown cells compared to controls.
These findings were also supported by downregulation
of genes such as Rho GTPase activating proteins, p21
(CDKN1A) activating protein, and p21-activated kinase
(PAK)-1 interacting protein, which are known to be
involved in the adhesion process [20]. Similarly,
miRNA-155 knockdown significantly inhibited WM cell
migration in response to stromal derived factor-1 (SDF-
1), an important regulator of migration in B cells. In
addition, while adherence of both non-transfected or
control probe-transfected WM cells to BM stromal cells
triggered 34% and 33% increase in proliferation, any sig-
nificant increase in the proliferation rate of miRNA-155
knocked down WM cells has been described, indicating
Figure 1 miRNA aberrations and hypoacetylated histones drive WM pathogenesis. WM tumor cells present with increased level of miRNA-
155, together with increased expression of HDACs and reduced expression of HATs, leading WM clone expansion and tumor progression.
(BMSCs: bone marrow stromal cells: miRNA-155: microRNA-155; HDAC: histone deacetylase; HAT: histone acetyltransferase)
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milieu. To better support the in vitro findings, effect of
miRNA-155 in regulating WM cell migration was also
confirmed in vivo, by using an in vivo homing model
[21]. In addition, mice injected with miRNA-155 knock-
down probe-transfected WM cells had prolonged survi-
val compared with mice injected with control probe-
transfected WM cells, with mean survival of 20 days vs
14 days (P < .001) and overall survival of 21 days vs 15
days, respectively.
WM cells present with a hypoacetylated status of histone,
partially driven by miRNA aberrations in the clonal WM
cell population
Histone acetylation is commonly deregulated in several
tumors. Nucleosomal histone acetylation homeostasis is
responsible for the transcriptional regulation of many
genes: particularly, hypoacetylation is associated with a
condensed chromatin structure leading to the repression
of gene transcription; while, hyperacetylation is asso-
ciated with a more open chromatin structure and activa-
tion of transcription [22,23]. This balance is modulated
by a tight regulation of histone deacetylase (HDAC) and
histone acetyl transferases (HATs) levels. In many
malignancies, this balance is deregulated; and tumor
cells present with an increased expression of HDACs
leading to decreased gene transcription [7,8]. HDACs
are enzymes that catalyze the removal of the acetyl
modification on lysine residues of proteins, including
the nucleosomal histones H2A, H2B, H3, and H4. In
addition, other induced genes include the cell cycle
kinase inhibitor p21
WAF1,p 1 6
ink4a,a n dp 2 7
Kip,p 5 3 ,N F -
YA, and GATA-1, leading to enhanced cellular func-
tions such as proliferation, cell-cycle, and survival [24].
Alterations in the balance between HAT and HDAC
activity in many cancers will lead to deregulated gene
expression and the induction of proliferation and survi-
val in tumor cells [25,26]. HDACs mediate the function
of oncogenic translocations in many malignancies
including promyelocytic (PML)-retinoic acid receptor
alpha (RARa) in acute promyelocytic leukemia [27].
Most of the aberrant HAT and HDAC activity has been
due to translocation, amplification, overexpression or
mutation in many malignancies, including hematological
malignancies [25,26,28]. Recent studies have demon-
strated that miRNAs may exert their activity by interfer-
ing with the epigenetic machinery, such as modulating
the expression of enzymes regulating DNA methylation
or histone modification [27-30]. For example, it has
been demonstrated that up-regulation of miRNA-449a
in prostate cancer cells exerts an anti-proliferative effect
on the tumor clone, supported by cell cycle arrest and
induction of a senescence-like phenotype and apoptosis
[30]. In addition, other miRNAs are responsible for
targeting histone methyltransferases. It has been recently
reported that miRNA-101 targets the enhancer of Zeste
homolog 2 (EZH2); the low expression level in several
tumor types could lead to up-regulation of EZH2 in
aggressive tumors with an invasive phenotype [31,32].
Recent studies have focused on the histone acetylation
status in WM cells and how miRNA may be responsible
for regulating histone acetylation in this disease.
miRNA-206 and -9* are respectively increased and
decreased in WM cells, as compared to normal cells
[14]. Predicted targets for the increased miRNA-206 and
decreased miRNA-9* included histone-acetyltransferases
(HATs) and HDACs, respectively, suggesting a possible
role of miRNA-206 and -9* in regulating histone acety-
lation in WM. Indeed, primary WM cells were charac-
terized by significant increased expression of HDAC-2,
-4, -5, -6, -8, -9, and significant decreased expression of
HAT-1, -2, and -3; together with a significantly higher
HDAC activity as compared to controls. Importantly,
functional studies revealed that acetyl histone-H3 and
-H4 were upregulated in pre-miRNA-9*- and -anti-
miRNA-206-transfected cells, with a higher acetyl his-
tone-H3 and -H4 up-regulation upon miRNA-9* modu-
lation. Moreover, miRNA-9*-dependent modulation of
HDAC activity lead to reduced WM cell proliferation
and increased WM cell toxicity, suggesting a key role of
miRNA-9* in regulation WM progression [6].
Conclusions
Modifications at the level of miRNAs have recently
gained considerable attention in the field of cancer
research. It has been recently identified an increased
expression of miRNAs-363*, -206, -494, -155, -184,
-542-3p, and decreased expression of miRNA-9* in pri-
mary bone marrow-derived WM tumor cells. Based on
this first observation, functional studies have been
focused on miRNA-155, and the oncogenic role of
miRNA-155 has been confirmed and validated in WM
cells. Indeed, miRNA-155 acts as a critical regulator of
proliferation of WM cells, where it specifically targets
WM cells even in the context of a bone marrow milieu.
This provides preclinical evidences to enhance our
understanding about the role of epigenetic changes in
WM pathogenesis. Indeed, if cytogenetic and molecular
studies on gene expression analysis at the miRNA level
have demonstrated minimal changes in WM cells, the
described significant differences in WM miRNA expres-
sion profiling improve our understanding of the under-
lying molecular changes that lead to the initiation and
progression of this rare disease. Importantly, miRNA-
155 may be regarded as a sufficiently restricted thera-
peutic target in WM.
In addition, subsequent studies have demonstrated
that that loss of miRNA-9* may be responsible for
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cells, contributing to the pathogenesis of this disease;
this also indicates the potential therapeutic value of syn-
thetic miRNA oligonucleotides as epigenetic modulators
with a mechanism of action similar to chemical HDAC
inhibitors.
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